OCTRU Senior Programmer
I have over 25 years’ experience in the IT industry, working in manufacturing, finance, telecommunications and the public sector before working in Clinical Trials when I joined the Oncology Clinical Trials Office (OCTO) in 2004.
I started work at OCTRU in October 2013 as Senior Clinical Trials Programmer and I'm looking forward to the challenge of developing world class IT systems to complement the world class research being performed by the constituent CTUs that make up OCTRU.
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Kerr RS. et al, (2016), Lancet Oncology
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D. et al, (2015), Gut, 64, 111 - 120
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Dutton SJ. et al, (2014), Lancet Oncol, 15, 894 - 904
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Rosmarin D. et al, (2014), J Clin Oncol, 32, 1031 - 1039
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Nicum S. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31